KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Merck (MRK) EBT (2016 - 2025)

Merck (MRK) has disclosed EBT for 17 consecutive years, with $3.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 17.99% to $3.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $21.1 billion, a 5.67% increase, with the full-year FY2025 number at $21.1 billion, up 5.67% from a year prior.
  • EBT was $3.4 billion for Q4 2025 at Merck, down from $6.7 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $6.7 billion in Q3 2025 to a low of -$5.3 billion in Q2 2023.
  • A 5-year average of $3.7 billion and a median of $4.1 billion in 2024 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 218.12% in 2023, then skyrocketed 303.81% in 2024.
  • Merck's EBT stood at $3.9 billion in 2021, then fell by 10.13% to $3.5 billion in 2022, then tumbled by 158.24% to -$2.0 billion in 2023, then surged by 303.81% to $4.2 billion in 2024, then dropped by 17.99% to $3.4 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's EBT are $3.4 billion (Q4 2025), $6.7 billion (Q3 2025), and $5.0 billion (Q2 2025).